DENVER--(BUSINESS WIRE)--Corgenix Medical Corporation (OTC QB: CONX.OB), a worldwide developer and marketer of diagnostic test kits, today announced that Zacks Investment Research has initiated coverage of the company. The following summarizes the Outlook and the entire report on Corgenix will soon be available on our website, www.corgenix.com.
Zack’s Investment Outlook on Corgenix Medical Corporation (CONX-QB):
“Corgenix is on the front-end of a transition away from reliance on certain legacy products to a more determined focus on growing higher potential areas of their business. Highlighted by the recent transfer of their international business and related joint product development agreements, the transition is expected to help jump-start revenue growth in the current fiscal year and form the basis for continued double-digit growth over the next several years. Based on comparable valuations, Corgenix’s shares trade significantly cheaper than warranted. We are initiating coverage of the company with a $0.50 per share price target and an Outperform rating.”
About Corgenix Medical Corporation
Corgenix is a leader in the development and manufacturing of specialized diagnostic kits for immunology disorders, vascular diseases and bone and joint disorders, including the world’s only non-blood-based test for aspirin effect. Corgenix diagnostic products are commercialized for use in clinical laboratories throughout the world. The company currently sells over 50 diagnostic products through a global distribution network and has significant experience advancing products through the FDA process. More information is available at www.corgenix.com.
About Zacks Small Cap Research
Founded in 1978 in Chicago, Zacks Investment Research is one of the largest independent investment research and consulting firms in the United States. The company provides individual and institutional investors with analytical tools and financial information necessary to the success of their investment process. Zacks’ models continually process stock reports issued by 3,000 analysts from 150 brokerage firms.
Forward-Looking Statements
Statements in this press release that are not strictly historical facts are “forward-looking” statements (identified by the words “believe”, “estimate”, “project”, “expect” or similar expressions) within the meaning of the Private Securities Litigation Reform Act of 1995. These statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products and services in the marketplace, competitive factors, changes in the regulatory environment, and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission. The statements in this press release are made as of today, based upon information currently known to management, and the Company does not undertake any obligation to publicly update or revise any forward-looking statements.